Furthermore, neutralizing antibody directed against CXCL16, alone or in combination with CXCR4 antagonist, significantly inhibited the migration of patient-derived breast cancer cells in our 3D CAF aggregate system. Here, CXCL16 is linked to breast carcinoma.